肺癌胸腔积液腔内化疗免疫序贯治疗疗效分析  

Evaluation of Chemotherapy and Sequent Immunotherapy for Lung Cancer Patients with Malignant Pleural Effusion

作　　者：刘飒[1] 王红阳[1] 喻昌利[1] 黄艳[1] 刘信荣[1] 

机构地区：[1]华北煤炭医学院附属医院呼吸科,063000

出　　处：《天津医药》2006年第8期542-544,共3页Tianjin Medical Journal

基　　金：唐山市科学技术研究与发展指导计划项目(项目编号:05134602e)

摘　　要：目的:综合观察化疗免疫序贯治疗肺癌胸腔积液的临床疗效及相关免疫指标的变化。方法:60例肺癌胸腔积液患者随机分为观察组和治疗组,各30例。两组尽量排净胸水,胸腔内注射顺铂和丝裂霉素各10mg,观察组2周后胸腔内注射白细胞介素(IL)-2,每3日1次,连续3周。检测两组治疗前和治疗后1个月外周血和胸水中T淋巴细胞和树突状细胞数量;3个月后观察治疗后胸水减少情况。结果:观察组临床缓解有效率达86.7%,与对照组43.3%比较,差异具有统计学意义(P<0.01)。观察组治疗后外周血和胸水中T淋巴细胞和树突状细胞的数量均明显高于对照组,差异有统计学意义(P<0.01)。结论:化疗免疫序贯治疗可增加免疫细胞数量,提高患者的生存质量。Objective： To evaluate the effectiveness of chemotherapy and sequent immunotherapy and the changes of relative immune parameters in lung cancer patients with malignant pleural effusion. Methods： Sixty patients were randomly divided into two groups： observed group（30 cases） and control group （30 cases）. In both groups, mitomycin （10 mg） and cisplatin （10 mg） were injected into pleural cavity after draining the pleural effusion thoroughly. Two weeks later, IL-2 was injected into pleural cavity in patients in observed group for every 3 days in 3 weeks. The numbers of dendritic cells and T lymphocytes in peripheral blood and pleural effusion for all patients were detected before and after therapy. The quantity of pleural effusion was evaluated 3 months after treatment. Results： The remission rate of clinical symptoms in observed group （86.7%） was much higher than in control group （ 43.3%, P〈0.01）. The numbers of dendritic cells and T lymphocytes were increased significantly in observed group than those in control group （P 〈 0.01）. Conclusion： Treatment of chemotherapy and sequent immunotherapy could rise the number of immunological cells and improve the quality of life of lung cancer patients with malignant pleural effusion.

关 键 词：肺肿瘤 胸腔积液 免疫测定 抗肿瘤联合化疗方案 

分 类 号：R734.205[医药卫生—肿瘤] R593.241[医药卫生—临床医学]